Abstract Prevalent as an acquired abnormality in cancer, the role of tumor protein p53 (TP53) as a germline mutation continues to evolve. The clinical impact of a germline TP53 mutation is often dramatic and affects the full life course, with a propensity to develop rare tumors in childhood and multiple common cancers of unexpectedly early onset in adulthood. In this article, we review the clinical relevance of germline mutations in the TP53 tumor suppressor gene to current healthcare practice, including the optimal ways to identify patients with Li-Fraumeni syndrome (LFS), to recognize the core cancers associated with LFS, and to develop strategies for early detection of LFS-associated tumors. Several TP53-targeted approaches to improve outcomes in LFS patients are also reviewed. A case report is used to highlight special TP53 testing dilemmas and unique challenges associated with genetic testing decisions in the current age of rapidly advancing genomic technologies.
Introduction
Li-Fraumeni syndrome (LFS; OMIM 151623) is an autosomal-dominant cancer syndrome caused by heterozygous germline mutations in the tumor protein p53 (TP53) gene. Half of the patients with LFS develop at least one LFSassociated cancer by age 30 years [1] [2] [3] [4] . This is in comparison with the 1 % chance of developing cancer by age 30 years in the general population [5] . Almost one third (15-35 %) of cancer survivors with LFS will develop multiple primary cancers over their lifetimes [6] [7] [8] [9] . LFS predisposes to radiation-induced malignancies as well [10] [11] [12] . Understanding the critical role of TP53 as the guardian of the genome has long suggested the potential for targeted cancer treatment.
In this review, we discuss the clinical relevance of TP53 mutations to modern day healthcare practices. We review the literature on the clinical picture of LFS, genetic testing criteria, issues related to genetic testing for LFS, and management recommendations. We also review emerging methods for early disease detection and promising TP53-targeted approaches to optimize outcomes.
Historical Milestones
As we rise to the challenge of merging the explosive number of key findings in the field of cancer biology, it is appropriate to review the medical impact of a gene that has revolutionized the field of cancer biology-TP53.
TP53 was first discovered in 1979 [13] [14] [15] during a period of time when the viral theory of cancer development was held in highest esteem. The viral theory suggested that viruses (such as the Simian virus 40, human papilloma virus, and Epstein Barr virus) were the principal drivers of oncogenesis. The identification and characterization of TP53 changed this theoretical paradigm, leading us into the current age of genomics and advancing our understanding of the role that oncogenes and tumor suppressor genes play in malignant transformation [16] [17] [18] [19] .
Because of TP53's key role as the 'guardian of the genome' [20] , more than half of all human cancers acquire mechanisms to impede TP53 function. TP53 is the most frequently mutated gene in human cancer [19] , with the prevalence of acquired TP53 mutations being highest in epithelial ovarian cancers (47 %), colorectal cancers (43 %), head/neck cancers (42 %), and esophageal cancers (41 %) [International Agency for Research on Cancer (IARC) database, R15 release] [21] . Cancers with acquired TP53 mutations are also associated with diminished survival rates, increased resistance to chemotherapy and radiation, and elevated relapse rates [22] [23] [24] .
TP53 was first detected in simian virus 40-transformed cells [14, 25] , with high levels of detectable p53 protein also seen in cells transformed by other biologic or physical agents [26, 27] in tumor cell lines [28] and in human cancers (especially leukemia and sarcoma) [29] [30] [31] [32] [33] .
In 1989, Lavigueur and colleagues accelerated TP53 research when they reported that 20 % of transgenic mice carrying a germline mutant TP53 gene developed lung adenocarcinomas, osteosarcomas, and lymphomas. They identified variable degrees of disease penetration, the occasional occurrence of simultaneous primary cancers, and the rare development of cancers such as rhabdomyosarcoma, skin carcinoma, fibrosarcoma, testicular carcinoma, and adrenal neuroblastoma [34] .
In 1996, Pfeifer and colleagues showed that TP53 pathway alterations could directly cause human cancer. Using the active metabolite of benzo [a] pyrene (a byproduct of cigarette smoke), Pfeifer's group induced TP53 mutagenesis, causing malignant transformation with unique genetic alterations [35, 36] . Their work refuted tobacco industry claims by providing the 'smoking gun'-scientific proof that cigarettes caused human lung cancer-and was, therefore, the lynchpin research that changed public health policies and practices in the USA and abroad [35, 37] . During a similar timeframe, Donehower and colleagues showed that TP53 did not appear to impair normal embryogenesis, growth, or development in genetically engineered mice [38] [39] [40] . Donehower's observations confirmed that germline mutations in the TP53 gene could be present without lethal consequences, making an inherited human disorder a plausible concept [14, 25, 26, 41] .
The original suggestion of a familial cancer syndrome of diverse tumors in humans was first proposed in 1969 by two physician-scientists, Frederick P. Li and Joseph F. Fraumeni, Jr., after they identified aggressive soft tissue sarcomas in young siblings and their biologically related cousins [42] . Over a 20-year period, they defined and refined a clinical syndrome that was ultimately confirmed, by segregation analysis, to be of genetic etiology and given the moniker 'Li-Fraumeni syndrome' (LFS) [3, 9, 43, 44] . Molecular genetic testing for TP53 germline mutations was developed in 1990 by David Malkin and colleagues [45, 46] and was quickly used as a screening tool to identify patients with hereditary forms of cancer [47] [48] [49] . In the early 1990s, Louis Strong and colleagues were the first to develop cancer-specific risk estimates, improving clinical care for families with LFS [50] . These major landmarks in TP53 history have formed the foundation for the modern era of scientific advancements in TP53-related research and clinical care [41] .
Li-Fraumeni Syndrome Core Cancers
While many tumor types can be seen in patients with LFS, four core cancers (breast, sarcoma, brain, and adrenocortical carcinoma [ACC]) make up about 80 % of LFSassociated tumors [1, 43, 44, 51] .
Breast Cancer
Breast cancer accounts for about 25-30 % of all LFSassociated tumors [1, 51, 52] . This is believed to account for at least part of the difference in lifetime cancer risk between women and men (nearly 100 vs. 73 %, respectively) [53] . Breast cancer is most predictive of the presence of a germline TP53 mutation when it is diagnosed before age 30-35 years in a woman with a family history of a first-or second-degree relative with a core LFS cancer (other than breast cancer) [1, 54, 55] . Women with LFS-associated breast cancer tend to present at an earlier age (in their 20s or early 30s) with more advanced-stage disease (i.e., tumors of [5 cm and axillary node disease) at the time of initial diagnosis. Recent studies have begun to describe the phenotype of breast cancers in TP53 mutation carriers [56] [57] [58] . All three studies found that the majority of breast tumors were human epidermal growth factor receptor type 2 (Her2)/Neu positive, and Melhem-Bertrandt et al. found a significantly greater number of Her2/Neu-positive tumors among TP53 carriers than among non-carriers (p = 0.0001; Table 1 ) [57] . Therefore, the emerging phenotype of a classic LFS-associated breast cancer appears to be ductal in histology; estrogen receptor (ER) positive, progesterone receptor (PR) positive, and Her2/Neu positive; and diagnosed in patients younger than age 35 years.
Sarcomas
Sarcomas account for another 25-30 % of all LFS-associated tumors [1, 51, 59, 60] . Multiple types of soft tissue sarcomas and osteosarcoma are associated with LFS, but Ewings sarcoma, gastrointestinal stromal cell tumors, desmoids tumors, and angiosarcomas have not been reported in LFS [59] . A recent study by Ognjanovic et al. compared sarcomas diagnosed in TP53 mutation carriers in the IARC TP53 database (n = 236) with sarcoma diagnoses in the Surveillance, Epidemiology, and End Results (SEER) database (n = 34,671) [59] . They found that 67 % of sarcomas in TP53 mutation carriers occurred before age 20 years, compared with only 11.9 % in the SEER database; in TP53 carriers, only 4.4 % of sarcomas occurred after age 50 years, while 62.7 % were diagnosed after age 50 years in the SEER database. The age distribution of sarcomas in TP53 mutation carriers is biphasic, with one peak in childhood and another between ages 20 and 40 years [59, 60] .
Brain Tumors
Brain tumors occur in 9-16 % of individuals with TP53 mutations [1, 51, 60, 61] . Glioblastomas/astrocytomas are the most common, but medulloblastoma, ependymoma, supratentorial primitive neuroectodermal tumors, and choroid plexus tumors may also be seen [61, 62] . Despite limited sample sizes, a compelling body of evidence supports the association between choroid plexus tumors, particularly choroid plexus carcinomas (CPCs), and TP53 germline mutations [1, 22, [63] [64] [65] . Gonzalez et al. reported that all eight individuals in their cohort with choroid plexus tumors (type not specified) and no additional personal or family history reported were positive for a germline TP53 mutation [1] . Other studies have reported prevalence rates between 36 and 44 % in patients with CPCs, many of whom also met the classic LFS or Li-Fraumeni-Like syndrome (LFL) criteria [22, 65] . As with sarcoma, there appears to be a biphasic age distribution of brain tumors in those with TP53 mutations, with the highest prevalence rates occurring before age 10 years and after age 20 years [51, 60] .
Adrenocortical Carcinomas
ACC accounts for 10-14 % of cancers in TP53 mutation carriers overall [1, 60] . While ACC has been diagnosed in individuals with LFS at a wide range of ages, it is considered a hallmark of LFS when diagnosed in childhood [1, 60, 66] . The IARC TP53 database reports a median age of ACC diagnosis among TP53 mutation carriers of 4.8 years versus 41.9 years among sporadic cases of ACC [60] . Gonzalez et al. found that 80 % of individuals in their cohort with ACC diagnosed under age 18 years had TP53 mutations [1] . The highest prevalence rates of ACC are reported in carriers of the Brazilian founder mutation, TP53 R337H. The R337H mutation is present at a high frequency in southern Brazil (about 1 in 300 individuals) [67, 68] , and evidence shows it to be a founder mutation [52, 69] . The frequency of this mutation among children with ACC in southern Brazil is 78-97 % [70, 71] . Initially, it was thought to be a low-penetrance mutation that predisposed only to ACC and not to other LFS-associated tumors [70] [71] [72] . However, more recent studies have found that the R337H mutation can be found in families with a broad spectrum of LFS-associated cancers [73, 74] .
Other Li-Fraumeni Syndrome Cancers
Beyond the four core LFS cancers, the next most frequently associated cancers include leukemia, lung cancer, colorectal cancer, skin cancer, gastric cancer, and ovarian cancer [1, 51, 60, [75] [76] [77] . All cancer types are diagnosed at younger than average ages. One study of colorectal cancer in LFS families found the average age at diagnosis to be 33 years, with four individuals diagnosed before age 21 years [75] . A study of gastric cancer in LFS families found an average age at diagnosis of 43 years (range 24-74), with four diagnosed before age 30 years [75, 76] . Genotype-phenotype correlations in LFS are predictive of the age at tumor onset, the level of tumor risk, and outcome in patients with TP53 germline mutations [51, 59, 60, 81] . Mutations in the DNA binding portion of the gene cause highly penetrant disease with very early-onset cancers; mutations outside the core DNA binding domain are associated with slower rates of tumor development [82] [83] [84] . Monti and colleagues utilized clinically annotated TP53 mutation data contained in the IARC database to correlate the functional properties of 104 TP53 germline mutations (with single amino acid substitutions) to cancerrelated outcomes. They (and others) used yeast-based functional assays to show that TP53 mutant alleles with reduced transactivation capability (including dominant negative acting proteins that reduce the transactivation 389  377  365  353  341  329  318  306  294  282  270  258  247  235  223  211  199  187  176  164  152  140  128  117  105  95  87  79  71  63  55  47  39  31  23  15  9  5 ability of the p53 wild-type protein) are associated with a higher frequency of multiple tumors and are more likely to be found in germline carriers with strong family histories of cancer [85] . Inherited genetic variations (including single-nucleotide polymorphisms [SNPs]) of the TP53 gene have been reported to impair p53 function in vitro and are associated with worse outcomes in specific subgroups of patients with cancer [86] .
Li-Fraumeni Syndrome: Genetic Testing
The diagnosis of LFS is based on an evolving set of clinical classification criteria, which have been established using the most salient aspects of family history and tumor-related characteristics. Deleterious (disease-causing) mutations in TP53 are found in only *70 % of the patients who meet the classic diagnostic criteria for LFS [43] , underscoring the importance of clinical suspicion and astute diagnostic skills when trying to identify affected patients and families. TP53 genotyping is typically performed by DNA Sanger sequence analysis and multiplex ligation-dependant probe assay or another technique to detect large rearrangements of portions of the gene [87] .
Testing Criteria
The following is a summary of when TP53 analysis may be recommended, when personal and family history should be evaluated for LFS, and when TP53 genotyping should be considered. The National Comprehensive Cancer Network (NCCN) guidelines recommend TP53 analysis for individuals who either meet the classic LFS criteria, meet the Chompret criteria, or have been diagnosed with breast cancer under age 30 years [88].
Published Criteria
Several sets of criteria have been developed over the past 20 years to help identify individuals with LFS who should be considered for TP53 testing ( Table 2 ). The first formal set of criteria developed (in 1988) is the classic LFS criteria; these criteria are the most stringent and are the ones used to make a clinical diagnosis of LFS (with or without the identification of a deleterious germline TP53 mutation) [43] . Later, broader criteria were developed by Birch et al. and Eeles et al. to identify families who are LFL [83, 89] . Chompret and colleagues developed another set of criteria, which were shown to provide the highest positive predictive value and, when combined with the classic LFS criteria, provided the highest sensitivity for identifying individuals with LFS (Table 3 ) [1, 90] . During the 3rd International p53 Mutant Workshop-LFS Symposium in 2007, the Chompret criteria were modified to develop a set of consensus-based criteria to identify TP53 carriers [60] . The Chompret criteria were most recently updated in 2009 to better identify families with milder phenotypes [84, 91] .
Breast Cancer at Age \30 Years
Some, including the NCCN, advocate testing for TP53 mutations in all individuals with breast cancer under age 30 who are negative for BRCA1 (breast cancer 1, early onset) [92] . They therefore propose that testing for BRCA1, BRCA2, and TP53 be performed simultaneously in this subset of patients.
Adrenocortical Carcinoma
Well-established criteria recommend TP53 analysis for any individual with ACC, regardless of age at diagnosis or family history [88, 91] . According to the published literature, however, it appears that the probability of finding a TP53 mutation is higher in patients with ACC diagnosed at age \40 years, especially those diagnosed in childhood [1, 60, 66] .
Choroid Plexus Carcinoma
The 2009 Chompret criteria recommended germline TP53 analysis for any patient with CPT, regardless of family history [1, 91] .
Gastrointestinal Cancer
TP53 mutation analysis should also be considered in cases of early-onset gastrointestinal cancer that meet the classic LFS or LFL criteria if other more common hereditary gastrointestinal syndromes have been ruled out [75, 76] .
Other TP53 Genetic Testing Considerations
In an attempt to develop an approach to finding other patients with LFS, Gonzalez and colleagues published the largest single report from a diagnostic testing lab [1] . Using clinical data from a TP53 clinical testing cohort of 525 patients submitted for testing, with 91 mutations identified, prevalence tables summarizing the individual and family characteristics associated with TP53 mutations were created. These tables can be used as clinical tools to help guide testing decisions (Table 4 ). Gonzalez and colleagues found that the highest germline TP53 mutation frequency rate (100 %; n = 5) was in patients who had at least one core cancer during childhood (prior to age 18 years) and a positive family history of cancer. TP53 testing is generally not recommended without a substantial probability of identifying a deleterious mutation. One of the most common and challenging clinical testing dilemmas is determining the most appropriate testing strategy for a woman who has tested negative for BRCA1 and BRCA2 mutations but has a family history consistent with a hereditary breast cancer syndrome. Indeed, the NCCN recommends TP53 genetic testing for patients with breast cancer diagnosed under age 30 years who have already tested negative for BRCA1 and BRCA2. However, in the absence of a very early age at breast cancer diagnosis, most families with breast cancer have an exceedingly low probability of carrying a TP53 mutation [91] . For example, if there are multiple cases of breast cancer in a family, but there are women interspersed between them who have lived past age 50 years and have not developed breast cancer, TP53 testing is usually not warranted. Common cancers historically associated with TP53 (such as leukemia and lung cancer), which are not among the more recently reported core Li-Fraumeni-associated cancers [44] , do not add to the likelihood of detecting a mutation [1] . Similarly, sarcoma patients over age 50 years are much less common in Li-Fraumeni families than in the general population [59] . However, as in all of medicine, there are rare exceptions to these rules, supporting the need for clinical judgment to navigate the nuances of strategizing the gene testing process.
6 Genetic Counseling for Li-Fraumeni Syndrome
Pre-and Post-Test Counseling
Decisions regarding germline TP53 testing should be made by healthcare professionals with specialized training in clinical cancer genetics and experience in interpreting complex, and potentially novel, variant gene mutations of uncertain clinical significance. All patients should have cancer genetic counseling prior to initiating the testing process, and access to long-term counseling to support the educational and psychosocial needs of LFS patients and their families.
Risk for Family Members
Most TP53 mutations have been inherited from a parent. After identifying a mutation, the proband's parent with any pertinent cancer history or family history should be tested first to establish the lineage of the mutation; otherwise, both parents should be tested. A family history can appear negative because of a limited family structure or incomplete penetrance of the mutation. The frequency of de novo mutations is not well established; however, on the basis of two studies, the de novo rate has been estimated to be as low as 7 % (5 of 75) and as high as 24 % (4 of 17) [53, 93] . Siblings and offspring of the proband should also be tested. If one of the proband's parents carries the TP53 mutation, each sibling has a 50 % risk of having the mutation. If neither parent is found to carry the mutation, the risk to siblings is low, but they should be tested because of the possibility of germline mosaicism. Offspring of a proband have a 50 % risk of carrying the mutation.
Testing of At-Risk Unaffected Children
For some time, testing of at-risk minors for identified TP53 mutations has been controversial because of the lack of proven surveillance or prevention strategies and concerns about informed consent, stigmatization, and discrimination [94] . However, because of emerging screening protocols showing efficacy in reducing mortality from TP53-related [95] , testing of at-risk children is now considered.
Preimplantation Genetic Diagnosis
Preimplantation genetic diagnosis (PGD) is available for high-risk couples seeking to avoid an affected pregnancy. PGD uses a standard in vitro fertilization procedure, allowing an embryo to be tested for an identified diseasecausing TP53 mutation prior to being transferred to the uterus [96] . PGD for LFS is one of the most compelling uses of this technology, among all cancer-predisposing syndromes, because of the early age at the onset of cancer and the significant risk of death by early adulthood [97] . PGD for TP53 mutations has been described and successfully performed [98] . Prenatal diagnosis of LFS, using amniocentesis or chorionic villus sampling, is another option to avoid having an affected child. Such an approach has been described but, because of the consideration of termination of an affected pregnancy, it is controversial and psychologically difficult for families [99] .
Psychological Considerations
Psychological functioning in individuals and families considering germline TP53 testing is an understudied but important aspect of clinical decision making and should be addressed throughout the counseling process. Peterson et al. studied individual perceptions of cancer risk and psychological distress in 92 members of 15 LFS-families. They found that increased psychological distress was associated with poor quality of life and a higher perceived risk of carrying a TP53 germline mutation. Interestingly, they also found that study participants with no personal history of cancer reported more psychological distress than those personally affected by cancer. Increased distress was also seen in participants who had a larger number of relatives affected by cancer [100] . Another study of 119 individuals considering TP53 testing found that study participants who lacked social support were more prone to report clinically relevant levels of distress [101] . TP53 germline carriers did not show higher levels of distress than non-carriers or those who declined testing. A substantial proportion of the overall group (23 %) reported clinically relevant levels of distress [101] . Partners of patients with a high probability of carrying a TP53 germline mutation have been reported to have elevated levels of distress and have expressed a desire for psychosocial support services [102] . Collectively, these reports support the need for comprehensive counseling services, including psychosocial counseling, for individuals and families considering TP53 germline testing [100, 101] .
Duty to Warn
When patients are reluctant to share relevant genetic information with family members, physicians may have to consider how to balance the patient's privacy with the interests of at-risk family members who can benefit from available screening and interventions. However, warning the relatives without the patient's consent is not consistent with the provider's ethical obligation to the patient and could be at odds with state and federal privacy laws. Instead, it is appropriate for providers to encourage patients to share such genetic information with relatives in a manner that is deliberate but not coercive [103] .
New Challenges to Informed Consent: TP53 Mutation Discovery with Genomic Approaches
With the growing availability and use of whole-genome sequencing, whole-exome sequencing, whole-genome arrays, and multi-gene panels comes the increased likelihood of unintentionally or unexpectedly identifying a TP53 mutation carrier. There have already been some case reports of this in the literature. One case was discovered through whole-genome array comparative genomic hybridization done on a child with mental retardation and no family history of cancer [104] . Another case was discovered through whole-genome sequencing performed on a patient with myelodysplastic syndrome and a history of premenopausal breast and ovarian cancer who had normal genotyping for BRCA1 and BRCA2 and no family history suggestive of a hereditary cancer syndrome [105] . These cases bring up important and complicated questions about how to ensure an adequate informed consent process for genomic testing, maintain health information privacy, and provide appropriate mechanisms for test result disclosures [106] [107] [108] . Employing these molecular strategies, especially on a research basis initially, will help us to gain a broader phenotypic picture of hereditary cancer syndromes such as LFS [77, 106, 109] .
Management of Li-Fraumeni Syndrome Patients
Guidelines for the management of patients with LFS have been published by the NCCN and include the following recommendations for early detection of disease: (i) children and adults should undergo comprehensive annual physical examination; (ii) women should undergo agespecific breast cancer monitoring that is routine for women with an increased inherited risk (which includes annual mammograms, breast magnetic resonance imaging [MRI] [110] , and clinical breast examination beginning at age 20-25 years or even earlier, depending on the youngest age at onset in the family) and should consider the option of risk-reducing mastectomy; and (iii) all should see a physician promptly for evaluation of lingering symptoms and illnesses [88] . Because of the challenges of interpreting the results of mammographic images of dense breast tissue in young women and the need to reduce lifetime exposure to radiation, the ACS recommends delaying the use of yearly mammograms in women with LFS until after age 25-30 years [111] . The NCCN also indicates that MRIonly screening may be sufficient between ages 20 and 30 years [88] . The NCCN prevention guidelines also include recommendations that adults can consider colonoscopy every 2-5 years (beginning no later than age 25 years); that individuals should undergo organ-targeted surveillance, depending on the pattern of cancer observed in the family; and that the option to participate in novel screening approaches (such as total-body MRI and brain MRI; see Sect. 7.1) should be discussed [88].
Enhanced Surveillance
Historically, enhanced surveillance for early disease detection in LFS patients beyond what is recommended in the NCCN guidelines has been considered investigational, primarily because of the lack of a proven survival benefit [112, 113] . However, recent reports show that enhanced screening protocols can detect early-stage disease and improve outcome in LFS patients [95, 113, 114] .
The first successful LFS-screening study incorporated F18-fluorodeoxyglucose-positron emission tomography/ computed tomography (PET-CT) imaging into an enhanced clinical surveillance regimen. The PET-CT study, conducted by Masciari et al, successfully identified cancer in 20 % (n = 3) of the 15 asymptomatic LFS individuals who were studied [113] . Two LFS patients had papillary thyroid cancer (stage II and stage III); one LFS patient had stage II esophageal adenocarcinoma. This study laid the foundation for a subsequent study by Villani et al., wherein there was an effort to minimize screening-associated ionizing radiation exposure [95] .
Villani et al. conducted a prospective, observational study of eight LFS families [95] . The 33 asymptomatic germline TP53 mutation carriers who were studied selfselected to be followed with enhanced surveillance (n = 18) or routine institutional follow-up care (n = 16; one LFS patient was in both groups). The surveillance protocol has been published and included physical examinations with targeted biochemical monitoring and radiologic imaging (with ultrasounds, brain MRI scans, and rapid total-body MRI scans) [95] . The overall survival at 3 years was excellent (100 %) in the surveillance group but only 21 % in the group without enhanced surveillance (95 % CI 4-48 %; p = 0.0155). Ten tumors were identified in seven members of the surveillance group; the five cancers that were detected were CPCs (n = 2), ACCs (n = 2), and one malignant fibrous histiocytoma. Three low-grade gliomas and one case of myelodysplastic syndrome were also detected in this group [95] . This is the first reported data that clearly show a survival benefit from enhanced surveillance in LFS patients. Because of the rarity of LFS, it is not realistically feasible to conduct outcome studies using large-scale, randomized, clinical trial study designs. It is, however, reasonable to utilize well-developed prospective studies, such as the one conducted by Villani et al. [95] , to inform decisions about advanced clinical care options for LFS patients.
Current biochemical screening tests for LFS patients include standardized tumor-based assays, such as 17-hydroxyprogesterone, to help detect ACC. However, several research-based testing methodologies are beginning to show promise as future tools for early disease detection and risk stratification for LFS patients. For instance, genomic assessment of copy-number variation (CNV) can yield a pattern associated with LFS-associated cancers compared with other cancers, and may identify early-stage disease in asymptomatic germline TP53 mutation carriers [115] . In one study, germline TP53 mutation carriers had a 4-8 fold increase in CNV, and affected TP53 carriers had much greater CNV than unaffected carriers [115] . Recently, LFS has been associated with shortened telomere length [116, 117] . Telomere length may be a reliable marker for assessing cancer risk and for determining the most appropriate timeframe to begin enhanced surveillance regimens for LFS carriers.
Other Considerations in Breast Cancer Risk
Reduction and Screening
As part of individualized preventative care, risk-reducing mastectomy should be offered to women with LFS as an option to reduce primary breast cancer risk [88] . LFS patients with breast cancer should be encouraged to consider mastectomy, rather than lumpectomy, to minimize the risk of developing new primary breast cancers and to avoid developing radiation-induced malignancies [88, 112] . Mammography has diminished efficacy in women with LFS, predominantly because of the increased mammographic densities seen in these young premenopausal women [118, 119] . In addition to limiting the effectiveness of mammography, increased mammographic densities have been associated with elevated breast cancer risk in women with hereditary and sporadic forms of breast cancer [120, 121] . Because interventions that modify the hormone effect (e.g., oophorectomy and tamoxifen) have been shown to reduce mammographic densities and breast cancer risks in younger women, Weitzel et al. developed an open-label pilot study to test the efficacy, safety, and tolerability of a novel hormone-based approach to chemoprevention in young women at risk of hereditary breast cancer [122] . This hormonal chemoprevention regimen included daily intranasal sprays of the gonadotropin-releasing hormone agonist deslorelin combined with ultralow-dose estradiol, replacement testosterone, and intermittent doses of oral medroxyprogesterone acetate. In this small series (n = 6) of premenopausal women with germline BRCA1 mutations, mammographic density was significantly reduced at 12 months (median absolute decrease 8.3 %; p = 0.043; representing a 29.2 % median reduction in mammographic percentage density). This study suggests that hormone-based chemoprevention options may expand the non-surgical cancer risk-reduction options available to women with LFS.
Case Example
The proband in this case example [95, 123] was a 31-yearold male who had been diagnosed with aplastic anemia at age 22 years, for which he received allogeneic hematopoietic stem cell transplantation (HSCT). His family history (see pedigree, Fig. 3 ) was significant for a son who was diagnosed with CPC just before one year of age. The proband's father was diagnosed with lung cancer at age 60 years and died at age 62 years. The proband presented for TP53 testing after his son was found to have a TP53 mutation. Because of his prior history of HSCT, a buccal sample was submitted for testing and was found to contain wild-type (normal) TP53. His wife was also tested and found to carry wild-type TP53. At this point, it was determined that even a buccal specimen would contain mostly donor DNA (because of peripheral blood contamination) and that a tissue biopsy would be needed. A tissue sample from the proband was analyzed, and a deleterious TP53 mutation was identified. The proband had another child, a 4-year-old asymptomatic daughter, who was tested and found to carry the same TP53 mutation. Given the mutation and her brother's history, she underwent a brain MRI, and two tumors were identified: a low-grade glioma and a CPC. Since her initial diagnosis, she has done very well, with no recurrence of the CPC. However, an abdominal ultrasound subsequently detected an adrenal cortical carcinoma, which was resected, and she has remained in complete remission. Unfortunately, the proband's son passed away a short time later. Despite the tragedy, this remarkably resilient family was able to see the potential importance of the genetic approach and became founding members of a new advocacy and support group for families with TP53 mutations (the LFS Association; http://www.lfsassociation.org/).
Case Discussion
There are many genetic testing and genetic counseling issues to consider in this case example. Since aplastic anemia is not one of the typical LFS malignancies, the only criterion for TP53 testing that was met was the 2009 Chompret criteria, because of the CPC in the son. As discussed above, testing for TP53 mutations in children has been quite controversial in the past but is gaining acceptance because of recent data showing a benefit from screening regimens. This case is an excellent example of how testing the second child for the previously identified mutation allowed for the screening and early detection of malignancy and, ultimately, improved survival. Another important consideration is that of genetic testing in individuals who have had HSCT. While genetic testing is usually performed on DNA isolated from a blood sample, this would not be accurate in individuals who have undergone HSCT, as the DNA in their blood would be that of their donors. In these cases, a tissue sample that will provide enough DNA for analysis must be provided, such as a skin biopsy or sperm sample, from which lymphocytes can be cultured. The last issue related to this case is that of PGD. This particular couple was not interested in having more children, but PGD is an option that should be discussed for families with LFS.
9 Treatment of TP53-Related Malignancies
Choroid Plexus Carcinoma
CPCs are associated with extremely poor outcomes in the pediatric patient population. Typically, these patients require treatment with aggressive protocols that include myelosuppressive chemotherapy and brain radiation (with significant developmental and intellectual consequences) [65, 124] . In a recent study of 64 choroid plexus tumors from children (with and without LFS), more than 90 % of CPCs demonstrated TP53 dysfunction, either due to deleterious TP53 germline mutations (*50 %) or due to somatic TP53 sequence variants involving TP53 codon 72 or MDM SNP 309 [125] . High-resolution SNP arrays revealed extremely high total structural variation (TSV) in TP53-mutated CPC tumor genomes (p = 0.006 in mutated vs. TP53 wild-type tumors; p = 0.004 in mutated vs. choroid plexus papillomas) [125] . High TSV was predictive of tumor progression (p \ 0.001) [125] . In addition, 14 out of 16 children with TP53 wild-type tumors had significantly favorable outcomes without radiation, with a mean follow-up time of 10.2 years (range 2.4-20 years). This and similar studies [65, 124, 125] show that children with CPCs can be stratified on the basis of TP53 mutational status into favorable and unfavorable risk groups, allowing a subset of children to benefit from the opportunity to avoid radiation therapy. In addition to advancements in risk stratification, novel therapeutic options are being explored.
For instance, poly (ADP-ribose) polymerase-1 (PARP1), a DNA repair protein, has been studied in an assortment of malignancies and may be protective against therapyinduced DNA damage. There is early evidence that PARP inhibition may be a therapeutic target that can trigger selective cell death in high-grade brain cancers (including CPCs) [126] .
Hematopoietic Malignancies and Stem Cell Transplantation
TP53 mutation carriers are 100 times more likely to develop leukemia; however, only 3 % of LFS patients develop a hematopoietic malignancy. LFS-associated leukemia tends to be very aggressive and is associated with a poor prognosis, complex karyotypes, and chromosome abnormalities seen in patients with therapy-related myelodysplastic syndrome [11] . TP53 alterations were the first biologic marker to become incorporated into risk stratification and upfront treatment decisions for chronic lymphocytic leukemia (CLL) patients treated in randomized clinical trials [127, 128] . TP53 inactivation in CLL predicts an ultra-high-risk group of patients with fludarabine-resistant disease and median survival times of less than 12 months [128] [129] [130] [131] . Therefore, the European Research Initiative on CLL has recommended that TP53 mutation analysis be performed for all CLL patients and that those with TP53 mutations be considered for allogeneic stem cell transplantation in the first remission. Studies have shown that alemtuzumab-based regimens may provide complete responses in this treatment-resistant group of patients [132] .
Future Directions for Therapies
A number of strategies have been explored to target TP53-associated cancers and improve outcomes for patients with somatic and germline TP53 mutations. For instance, single gene targeting strategies that utilize viral vectors (such as Advexin and ONYX-015) have shown some promise [4, [133] [134] [135] . However, current approaches target more generalized TP53 pathway functions, aiming for low toxicity profiles that could support the possibility of incorporating these therapies into multi-agent combination regimens. A few representative approaches are described below.
Monoclonal Antibodies
Monoclonal antibodies have been shown to improve outcomes in several disease types, including some promising laboratory and early-phase clinical trials showing an apoptotic affect against TP53-associated leukemia [136, 137] . Humanized monoclonal antibodies such as trastuzumab (Herceptin Ò ) are currently being used to treat several malignancies, including breast and stomach cancer [138, 139] . Trastuzumab binds to the extracellular domain of Her2, inhibiting cell growth and targeting cancer cells for destruction by the patient's immune system. Trastuzumab has been shown to significantly improve outcomes for the 20-30 % of patients with Her2-positive breast cancer; this includes patients with metastatic disease who are unlikely to be cured by any other means [140, 141] . Recent studies have begun to identify a unique LFS-breast cancer phenotype that is ductal in histology with estrogen, progesterone, and Her2 receptor positivity [56] [57] [58] . This Her2-positive phenotype suggests that clinical trials incorporating trastuzumab into front-line therapy for young women with LFS-breast cancer should be considered.
Small Molecules
Various small molecules are being explored to try to restore normal TP53 function to deficient cells. Reactivation of wild-type TP53 activity can be a successful strategy and has caused regression of lymphoma and liver cancer in TP53-deficient in vivo model systems [142] [143] [144] . A number of promising small molecules have been identified using in silico drug screening technologies. These small molecules (currently named PhiKan083, PRIMA-1, CP31398, WR1065, MIRA-1, STIMA-1, RETRA, Nutlin-3, and RITA) reactivate TP53 functional pathways, using mechanisms such as raising the melting temperature of the mutant protein to trigger reactivation of function, normalizing the folding conformation of the mutant protein to restore its ability to bind to DNA, or reactivating TP53 wild-type function in TP53-associated cancers [145] [146] [147] [148] [149] [150] . Although promising, the strategy of TP53 reactivation much be approached with some caution because of reports that increased TP53 expression is associated with treatment resistance in breast cancer [151] .
Metabolic Therapy
Autophagy is an evolutionarily conserved process of selfdegradation of cellular components such as very long-lived proteins and damaged (or excessive numbers of) organelles. Current research suggests that autophagy has two somewhat contradictory functions. It protects the host by suppressing early stages of tumor development, yet it supports the survival of established tumors that are threatened by starvation or chemotherapy. TP53 regulates the expression of key genes in the pathways required for both autophagy and adaptive metabolic responses to stressors through the 5 0 adenosine monophosphate-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) pathways [78] . Metformin is a drug that regulates cellular metabolism by activating the TP53-AMPK pathway.
Metformin is a well-tolerated, commercially available drug, commonly used to treat type II diabetes mellitus. Epidemiologic studies have shown decreased cancers in diabetes patients receiving treatment with metformin [152] [153] [154] [155] . This clinical observation has been supported by preclinical reports showing that metformin preferentially inhibits growth of cells lacking functional TP53 [156] . Similarly, studies have shown prolonged overall survival of more than 5 months in TP53-deficient mice treated with metformin. These observations are very encouraging, and clinical trials aimed at using metformin to reduce cancer risk in LFS patients are under consideration by members of the Li-Fraumeni Exploration (LiFE) Research Consortium (http://epi.grants.cancer.gov/Consortia/single/life.html).
Heavy-Ion Cancer Therapy
Heavy-ion radiation therapy utilizes charged particles (heavier than helium ions) to give increased dosages of precisely targeted radiation to cancers, achieving good cancer control while minimizing damage to nearby organs. This highly effective form of linear energy transfer has been shown to induce cell death in a TP53-independent manner (possibly through a pathway that activates the mitochondrial apoptotic factor caspase 9). These findings suggest that heavy-ion therapy may be a very well-tolerated way to improve outcomes for patients with TP53 mutated or TP53 null cancers. The practical application of this technology is limited by prohibitive costs and the need for impractical, huge accelerators; thus, there are only a few heavy-ion facilities available worldwide. Even so, advances in TP53-independent apoptosis-related gene pathways could lead to similar, more near-term applications of heavy-ion therapies that target aberrant TP53-associated pathways [157] .
Summary
Although most TP53-targeted therapies are still in the early phases of testing, the field of TP53-directed research remains very active and is expanding rapidly. Notably, a workshop on November 2, 2010, at the National Institutes of Health in Bethesda (MD, USA) brought together clinicians and scientists, as well as individuals from families with LFS, to review the state of the science, address clinical management issues, stimulate collaborative research, and engage the LFS patient community. This workshop led to the creation of the LiFE Research Consortium to promote better understanding of the syndrome and improvement of the lives of individuals with LFS [123] . Following that inaugural meeting, the LFS Association (www.lfsassociation.org) was created as a resource designed to provide a wide range of information, advocacy, and support services for individuals and families with LFS. The newly established advocacy group was created to facilitate effective communications, among other tasks, between LFS families and the clinical and scientific members of the research consortium. By summarizing these 40 years' worth of dedicated efforts to advance treatment and cancer prevention options for people with this rare syndrome, we hope to encourage and provide a voice for our international group of research partners and the LFS patients and families who are living each day with hope for a better tomorrow.
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